This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutEnbrel commitment to inflammation careDosingDosingEnbrel dosing and administrationMyClic pre-filled penPre-filled syringeMyClic administrationPowder and solventEfficacy and SafetyEfficacy and SafetyEnbrel therapeutic indicationsRheumatoid arthritisJuvenile idiopathic arthritisPsoriatic arthritis
Ankylosing spondylitisPlaque psoriasisSupport & ResourcesSupport & ResourcesEnbrel patient supportOrder patient materialsEnbrel: Sleeve for MyClic pre-filled pensVideosMaterials

Information on how to access Enbrel® (etanercept) and Maxtrex (methotrexate) prescribing information and adverse event reporting can be found at the bottom of the page.

Enbrel®: commitment to inflammation care

Transforming lives for over 20 years

Anti-TNF agents, including Enbrel, have revolutionised the treatment of chronic inflammatory diseases.1 Pfizer is committed to using our extensive experience and expertise to continue to support and transform the lives of patients living with these debilitating diseases.

Enbrel has extensive clinical experience across a range of inflammatory diseases2,3

  • Enbrel was the first approved anti-TNF agent for rheumatoid arthritis and is now approved to treat six additional inflammatory conditions:2,4-7
  • Enbrel has over 7 million patient-years exposure across all indications3
  • To date, there have been more than 450 trials conducted with Enbrel and over 7,000 publications
Watch Enbrel's Heritage Video  (watch now...)Confidence of qualityAnti-TNF agents, including Enbrel, have revolutionised the treatment of chronic inflammatory diseases.1 Pfizer is committed to using our extensive experience and expertise to continue to support and transform the lives of patients living with these debilitating diseases.

The manufacture of original biologics and biosimilars is challenging. Pfizer has over 20 years’ experience manufacturing Enbrel, and fully understands the complex processes involved

At the Grange Castle facility where Enbrel is manufactured, Pfizer has amassed extensive expertise in controlling production lines to ensure the consistent delivery of a high quality biologic. To ensure quality:
  • Enbrel has been subject to 19 manufacturing improvements since 19988
  • ​20,000 hours of maintenance are performed annually on the equipment used to produce Enbrel8     
Every batch of Enbrel:        
  • Takes 43 days to create8
  •  Undergoes >20 testing procedures and 100s of quality control checks8
  •  Is produced in state-of-the-art facilities8          

Pfizer’s commitment and dedication ensures the manufacture of a high quality biologic for your patients.

A valuable partner to patients and the NHSAnti-TNF agents, including Enbrel, have revolutionised the treatment of chronic inflammatory diseases.1 Pfizer is committed to using our extensive experience and expertise to continue to support and transform the lives of patients living with these debilitating diseases.

Pfizer is committed to being a trusted partner for healthcare professionals and centres, helping to shape the future of inflammation care. We are also committed to making a difference to the lives of patients across the UK

Pfizer is dedicated to delivering cost-effective and patient-centered care; funding home delivery and patient services to complement and enhance patient care

The Together online support programme  was developed in collaboration with Enbrel users. It gives patients content tailored to their condition, administration method and length of time they've been taking Enbrel. Pfizer aims to provide value for patients, clinicians and commissioners.Physicians and those with inflammatory conditions will continue to have access to a medicine they know and trust in a new and changing environment.Explore more Enbrel dosing and administration

Learn more about the dosing and administration of Enbrel, across indications.

 MyClic administration Loading Enbrel patient support

See what online support your patients have access to

 Find out more Loading

Prescribing information

Enbrel (etanercept) prescribing information,  Enbrel PI
Maxtrex (methotrexate) prescribing information, Maxtrex PI 
 


To return to the homepage click Enbrel (etanercept)

References:

Vincent FB et al. Ann Rheum Dis. 2013;72:165-178.Enbrel (etanercept) SmPC. Available at http://www.medicines.org.uk/emc [Accessed March 2021].Etanercept PSUR 27. February 2020Humira (adalimumab) SmPC.Remicade (infliximab) SmPC.Cimzia (certolizumab pegol) SmPC.Simponi (golimumab) SmPC.Data on file. New York, NY Pfizer Inc.
PP-ENB-GBR-1125. January 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​